Vivopower Plc (VIVO)

$2.13 +0.03 (1.43%)
Market Cap 26.31M
Revenue (ttm) 60,000.00
Net Income (ttm) -12.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -21,316.67%
Debt to Equity Ratio 1.45
Volume 165,600
Avg Vol 974,342
Day's Range N/A - N/A
Shares Out 12.53M
Stochastic %K 14%
Beta -1.57
Analysts Hold
Price Target $34.00

Company Profile

VivoPower PLC, together with its subsidiaries, provides energy solutions for customized and ruggedized fleet applications, battery and microgrids, and solar and critical power technology and services. It operates through Electric Vehicles, Sustainable Energy Solutions, Solar Development, and Digital Assets segments. The Electric Vehicles segment offers ruggedized battery-powered Electric Vehicle (EV) solutions, including conversion kits for fleet owners in the mining, agriculture, energy utility...

Industry: Software - Infrastructure
Sector: Technology
Phone: 44 203 667 5158
Address:
Blackwell House, Guildhall Yard, London, United Kingdom
StockFocusBoard
StockFocusBoard Apr. 7 at 8:41 AM
$VIVO medical technology company.
0 · Reply
PrimeControl
PrimeControl Apr. 7 at 8:13 AM
$VIVO medical technology company.
0 · Reply
spacmillitia
spacmillitia Apr. 7 at 7:42 AM
$VIVO sorry what do you want to discuss ?
0 · Reply
mikeDiscovery
mikeDiscovery Apr. 7 at 7:31 AM
$VIVO If everything is “fake,” then there’s nothing left to debate yet you’re here every day writing paragraphs. That’s the contradiction. People don’t spend this much time on something they think is worthless unless they’re trying to push a narrative. You’ve moved from questioning vehicles → to homologation → to suppliers → to profiles → now “everything fake.” That’s not analysis — that’s frustration. Also, careful throwing around “fake” at everyone. You’ve had your own failed calls and still stayed here repeating the same script. I won’t go further it wouldn’t help you anyway. At this point it just looks like you’re emotionally invested in being negative. Markets don’t reward that.
0 · Reply
spacmillitia
spacmillitia Apr. 7 at 7:29 AM
$VIVO Hey dumbass So we’re all very clear The company is fake The announcements are fake The strategy pivot is fake You are fake Now what is it you want to discuss ?
1 · Reply
mikeDiscovery
mikeDiscovery Apr. 7 at 7:27 AM
$VIVO You’ve moved from attacking the company to attacking profile pictures that usually happens when the argument runs out. Whether someone uses AI or not doesn’t change filings, disclosures, supplier issues, or timelines. You can silence 50 scholars with one fact but you can’t silence one idiot with 50 facts. That’s why you keep recycling the same claims and switching targets from EVs → crypto → profiles. If the thesis is strong, attack the numbers. If not, it becomes “fake accounts” and “ChatGPT” accusations.
0 · Reply
spacmillitia
spacmillitia Apr. 7 at 6:59 AM
$VIVO what is really offensive about this pump crew who are infesting this forum is how little effort they put into their fake profiles. Here’s the latest who all use the same chatgpt account. Try harder scammers …at least pay for the pro version
0 · Reply
jimwilson11
jimwilson11 Apr. 7 at 5:29 AM
$VIVO
0 · Reply
jimwilson11
jimwilson11 Apr. 7 at 5:28 AM
$VIVO
0 · Reply
jimwilson11
jimwilson11 Apr. 7 at 5:28 AM
$VIVO
0 · Reply
Latest News on VIVO
VivoPower Receives Nasdaq Approval of Ticker “TEMB” for Planned Tembo Listing at a Targeted Valuation of $838 Million

Mar 26, 2026, 9:10 AM EDT - 11 days ago

VivoPower Receives Nasdaq Approval of Ticker “TEMB” for Planned Tembo Listing at a Targeted Valuation of $838 Million

VivoPower Commences Strategic Share Conversion Program; Initial 2.96 Million Listed Class A Ordinary Shares Becoming Unlisted Restricted Class B Shares, Reducing Public Float

Mar 20, 2026, 9:32 AM EDT - 17 days ago

VivoPower Commences Strategic Share Conversion Program; Initial 2.96 Million Listed Class A Ordinary Shares Becoming Unlisted Restricted Class B Shares, Reducing Public Float

VivoPower Terminates $180 Million F-3 Registration Statement

Mar 18, 2026, 9:00 AM EDT - 19 days ago

VivoPower Terminates $180 Million F-3 Registration Statement

VivoPower Announces Effectiveness of New Stock Ticker “VIVO” and Corporate Name Change

Mar 16, 2026, 7:05 AM EDT - 21 days ago

VivoPower Announces Effectiveness of New Stock Ticker “VIVO” and Corporate Name Change

Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio

Feb 24, 2026, 8:00 AM EST - 5 weeks ago

Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio

SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

Jan 31, 2023, 1:56 PM EST - 3 years ago

SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger

Dec 12, 2022, 8:00 AM EST - 3 years ago

Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger

MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS

Nov 22, 2022, 8:00 AM EST - 3 years ago

MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TMX, VIVO, RFP, SBTX

Sep 26, 2022, 12:00 AM EDT - 3 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TMX, VIVO, RFP, SBTX

RFP

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, EGY, STCN

Aug 22, 2022, 9:34 AM EDT - 3 years ago

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, EGY, STCN

EGY RFP STCN

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAX

Aug 15, 2022, 9:00 AM EDT - 3 years ago

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAX

BHVN

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, ONEM, HNGR

Aug 8, 2022, 12:00 AM EDT - 3 years ago

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, ONEM, HNGR

MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS

Aug 5, 2022, 8:00 AM EDT - 3 years ago

MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS

Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Jul 29, 2022, 9:23 AM EDT - 4 years ago

Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

MERIDIAN BIOSCIENCE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

Jul 27, 2022, 10:10 PM EDT - 4 years ago

MERIDIAN BIOSCIENCE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

MERIDIAN BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

Jul 7, 2022, 6:59 PM EDT - 4 years ago

MERIDIAN BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

Meridian Bioscience agrees to $1.5 billion buyout by SD Biosensor, SJL Partners

Jul 7, 2022, 7:32 AM EDT - 4 years ago

Meridian Bioscience agrees to $1.5 billion buyout by SD Biosensor, SJL Partners

Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

Jul 7, 2022, 7:17 AM EDT - 4 years ago

Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter

Jul 7, 2022, 7:12 AM EDT - 4 years ago

Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Jun 20, 2022, 8:38 AM EDT - 4 years ago

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

May 26, 2022, 1:31 PM EDT - 4 years ago

Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

May 23, 2022, 1:13 PM EDT - 4 years ago

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

May 17, 2022, 3:33 PM EDT - 4 years ago

Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

May 6, 2022, 3:15 PM EDT - 4 years ago

Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

May 6, 2022, 8:00 AM EDT - 4 years ago

MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

May 2, 2022, 8:47 AM EDT - 4 years ago

Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter

Apr 7, 2022, 8:35 AM EDT - 4 years ago

Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter

Meridian Bioscience Launches Lyo-Ready™ qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection

Mar 29, 2022, 2:37 PM EDT - 4 years ago

Meridian Bioscience Launches Lyo-Ready™ qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer

Feb 21, 2022, 9:00 AM EST - 4 years ago

Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer

Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits

Feb 16, 2022, 9:05 AM EST - 4 years ago

Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits

Impactive Capital brings a sustainable brand of activism to Meridian Bioscience

Feb 12, 2022, 8:49 AM EST - 4 years ago

Impactive Capital brings a sustainable brand of activism to Meridian Bioscience

Why Meridian Bioscience's Shares Are Rising Today?

Feb 4, 2022, 11:30 AM EST - 4 years ago

Why Meridian Bioscience's Shares Are Rising Today?

MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY

Feb 4, 2022, 8:00 AM EST - 4 years ago

MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY

Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel

Jan 31, 2022, 11:45 AM EST - 4 years ago

Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel

Meridian Bioscience Launches Lyo-Ready™ qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Jan 28, 2022, 10:05 AM EST - 4 years ago

Meridian Bioscience Launches Lyo-Ready™ qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board

Jan 27, 2022, 2:05 PM EST - 4 years ago

Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board

Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022

Jan 10, 2022, 10:05 AM EST - 4 years ago

Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022

Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay

Jan 5, 2022, 10:15 AM EST - 4 years ago

Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay

Meridian Bioscience to Participate in the 2022 H. C. Wainwright Bioconnect Virtual Conference

Jan 4, 2022, 2:00 PM EST - 4 years ago

Meridian Bioscience to Participate in the 2022 H. C. Wainwright Bioconnect Virtual Conference

3 Stocks With Low PEG Ratios

Dec 14, 2021, 12:23 PM EST - 4 years ago

3 Stocks With Low PEG Ratios

AMPH JOUT

Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

Dec 2, 2021, 8:00 AM EST - 4 years ago

Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

Meridian Bioscience Announces Retirement of Chairman David Phillips

Nov 24, 2021, 9:05 AM EST - 4 years ago

Meridian Bioscience Announces Retirement of Chairman David Phillips

Meridian Launches Two New Air-Dryable™ Mixes for Isothermal Amplification, Powering Shortest Time-to-results in Point-of-care Testing

Nov 17, 2021, 10:05 AM EST - 4 years ago

Meridian Launches Two New Air-Dryable™ Mixes for Isothermal Amplification, Powering Shortest Time-to-results in Point-of-care Testing

Meridian Bioscience's Q4 Earnings Beat Expectations

Nov 12, 2021, 11:45 AM EST - 4 years ago

Meridian Bioscience's Q4 Earnings Beat Expectations

Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance

Nov 12, 2021, 7:30 AM EST - 4 years ago

Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance

Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay

Nov 10, 2021, 8:55 AM EST - 4 years ago

Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay

StockFocusBoard
StockFocusBoard Apr. 7 at 8:41 AM
$VIVO medical technology company.
0 · Reply
PrimeControl
PrimeControl Apr. 7 at 8:13 AM
$VIVO medical technology company.
0 · Reply
spacmillitia
spacmillitia Apr. 7 at 7:42 AM
$VIVO sorry what do you want to discuss ?
0 · Reply
mikeDiscovery
mikeDiscovery Apr. 7 at 7:31 AM
$VIVO If everything is “fake,” then there’s nothing left to debate yet you’re here every day writing paragraphs. That’s the contradiction. People don’t spend this much time on something they think is worthless unless they’re trying to push a narrative. You’ve moved from questioning vehicles → to homologation → to suppliers → to profiles → now “everything fake.” That’s not analysis — that’s frustration. Also, careful throwing around “fake” at everyone. You’ve had your own failed calls and still stayed here repeating the same script. I won’t go further it wouldn’t help you anyway. At this point it just looks like you’re emotionally invested in being negative. Markets don’t reward that.
0 · Reply
spacmillitia
spacmillitia Apr. 7 at 7:29 AM
$VIVO Hey dumbass So we’re all very clear The company is fake The announcements are fake The strategy pivot is fake You are fake Now what is it you want to discuss ?
1 · Reply
mikeDiscovery
mikeDiscovery Apr. 7 at 7:27 AM
$VIVO You’ve moved from attacking the company to attacking profile pictures that usually happens when the argument runs out. Whether someone uses AI or not doesn’t change filings, disclosures, supplier issues, or timelines. You can silence 50 scholars with one fact but you can’t silence one idiot with 50 facts. That’s why you keep recycling the same claims and switching targets from EVs → crypto → profiles. If the thesis is strong, attack the numbers. If not, it becomes “fake accounts” and “ChatGPT” accusations.
0 · Reply
spacmillitia
spacmillitia Apr. 7 at 6:59 AM
$VIVO what is really offensive about this pump crew who are infesting this forum is how little effort they put into their fake profiles. Here’s the latest who all use the same chatgpt account. Try harder scammers …at least pay for the pro version
0 · Reply
jimwilson11
jimwilson11 Apr. 7 at 5:29 AM
$VIVO
0 · Reply
jimwilson11
jimwilson11 Apr. 7 at 5:28 AM
$VIVO
0 · Reply
jimwilson11
jimwilson11 Apr. 7 at 5:28 AM
$VIVO
0 · Reply
jimwilson11
jimwilson11 Apr. 7 at 5:28 AM
$VIVO
0 · Reply
jimwilson11
jimwilson11 Apr. 7 at 5:28 AM
$VIVO
0 · Reply
Alin_als
Alin_als Apr. 7 at 5:26 AM
New to this space but VivoPower International PLC seems interesting The combination of EV focus and energy infrastructure feels aligned with where technology is heading $VIVO
0 · Reply
Sidk95
Sidk95 Apr. 7 at 5:20 AM
$VIVO
0 · Reply
Sidk95
Sidk95 Apr. 7 at 5:19 AM
$VIVO Just came across VivoPower while looking into the commercial EV space. Interesting that they’re focusing on fleet electrification and utility vehicles instead of consumer EVs. That market actually makes sense: • predictable fleet usage • fuel savings potential • ESG pressure on industries • smaller niche but real demand Not saying it’s huge yet, but the fleet conversion angle is different from most EV names. Worth watching how this develops.
0 · Reply
Shivi12
Shivi12 Apr. 7 at 5:17 AM
$VIVO $VIVO
0 · Reply
Dbeast007
Dbeast007 Apr. 7 at 5:16 AM
$VIVO Most EV discussions are about passenger cars, but industrial fleets are a different story. Predictable usage, centralized charging, and cost-driven decisions. Seeing some companies targeting this segment. VivoPower seems to be leaning in that direction. Not mainstream, but could be where adoption starts. $VIVO
0 · Reply
Naffi1
Naffi1 Apr. 7 at 5:13 AM
$VIVO
0 · Reply
OG_Stock1
OG_Stock1 Apr. 7 at 5:11 AM
Trying to understand this one. Looks like the focus is on commercial EV conversions rather than mass production. If companies can electrify existing fleets instead of replacing everything, that could lower adoption barriers. Still researching, but the model is different from most EV names. $VIVO
0 · Reply
Cag007
Cag007 Apr. 7 at 5:04 AM
$VIVO Noticed this name while looking at smaller EV plays. Seems like they’re not trying to compete with big auto companies, but instead focusing on utility and fleet electrification. $VIVO
0 · Reply
rahgeh
rahgeh Apr. 7 at 4:55 AM
$VIVO $VIVO
0 · Reply
rahgeh
rahgeh Apr. 7 at 4:55 AM
$VIVO
0 · Reply